Cyteir nets $40M for rad synthetic lethality platform — throwing another monkey wrench at cell repair
A cell is like a speedboat, says Cyteir Therapeutics founder Markus Renschler. When all parts are sound — the hull fortified, the engine steady — it’s smooth sailing. But you could go faster. You could drill a hole in the front, and sure you’d be in greater danger but you’d be gliding. At that point, though, a hole in the back would be deadly.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 73,100+ biopharma pros reading Endpoints daily — and it's free.